Soliqua

Primary Use

Soliqua is prescribed for adults with type 2 diabetes mellitus to help manage blood sugar levels. It combines two different types of medications: insulin glargine, a long-acting insulin, and lixisenatide, a GLP-1 receptor agonist.

How It Is Used

This medication is intended for use in conjunction with a healthy diet and regular physical activity. It is often prescribed when blood sugar levels remain high despite the use of other diabetes medications, such as metformin or basal insulin.

Limitations of Use

• Soliqua is not used to treat type 1 diabetes.
• It is not for the treatment of diabetic ketoacidosis (a serious condition involving high levels of blood acids).
• It has not been studied in people with a history of pancreatitis.
• It should not be used in combination with other GLP-1 receptor agonists or other insulin products.

Dual Action for Blood Sugar Control

Soliqua contains two active ingredients: insulin glargine and lixisenatide. Each component works in a different way to manage blood glucose levels throughout the day and after meals.

Insulin Glargine

Insulin glargine is a long-acting (basal) insulin. It mimics the insulin naturally produced by the body and works by:

• Helping cells in the body absorb sugar from the bloodstream to use for energy.
• Reducing the amount of sugar the liver produces and releases into the blood.

This component provides a steady level of insulin for about 24 hours, helping to keep blood sugar stable between meals and overnight.

Lixisenatide

Lixisenatide belongs to a class of drugs called GLP-1 receptor agonists. It mimics a natural hormone in the body to help lower blood sugar, particularly after eating. It works by:

• Signaling the pancreas to release more insulin when blood sugar levels are high.
• Decreasing the release of glucagon, a hormone that tells the liver to make more sugar.
• Slowing down the speed at which the stomach empties, which helps prevent blood sugar spikes after meals.

By combining these two medications, Soliqua addresses blood sugar management through multiple pathways in the body.

Common Side Effects

The most frequently reported side effects of Soliqua include:

• Nausea and diarrhea
• Headache
• Upper respiratory tract infections, such as the common cold
• Stuffy or runny nose and sore throat
• Injection site reactions, including redness, swelling, or itching

Serious Side Effects

While less common, some side effects can be severe and require immediate medical attention:

• Low blood sugar (hypoglycemia): This is a common but potentially serious side effect. Symptoms may include dizziness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, or a fast heartbeat.
• Pancreatitis: Inflammation of the pancreas can cause severe pain in the upper stomach area that may spread to the back, often accompanied by vomiting.
• Kidney problems: New or worsening kidney failure may occur, sometimes caused by dehydration from nausea and vomiting.
• Gallbladder problems: This may include gallstones or inflammation of the gallbladder.
• Low potassium (hypokalemia): Low levels of potassium in the blood can affect heart rhythm if not treated.
• Severe allergic reactions: Symptoms can include swelling of the face, lips, or tongue, difficulty breathing, severe rash, or fainting.

Pancreatitis

Inflammation of the pancreas (pancreatitis) has been reported with the use of GLP-1 receptor agonists like lixisenatide. Patients are monitored for persistent, severe abdominal pain that may radiate to the back.

Hypoglycemia

Low blood sugar is the most common side effect and can be life-threatening. Risk factors include changes in meal patterns, physical activity, or co-administration with other glucose-lowering medications.

Kidney and Gallbladder Issues

Lixisenatide may cause acute kidney injury or worsening of existing kidney problems, often associated with nausea, vomiting, or diarrhea leading to dehydration. Gallbladder problems, including gallstones and gallbladder inflammation, have also been reported.

Heart and Potassium Levels

Insulin products can cause a shift in potassium levels (hypokalemia), which may lead to respiratory paralysis or heart rhythm abnormalities if untreated. Additionally, using Soliqua with certain other diabetes medications, such as thiazolidinediones (TZDs), may increase the risk of heart failure.

Severe Allergic Reactions

Serious hypersensitivity reactions, including anaphylaxis and angioedema, can occur. Treatment must be discontinued immediately if an allergic reaction is suspected.

Suicidal Ideation Monitoring

While the FDA's evaluation has not found a definitive link between GLP-1 receptor agonists and suicidal thoughts or actions, healthcare providers may still monitor for changes in mood or behavior.

Pen Sharing

Injection pens must never be shared between people, even if the needle is changed, as this poses a risk for transmitting bloodborne pathogens.

Pregnancy

There is limited research regarding the use of Soliqua in pregnant women. Animal studies on lixisenatide, one of the active ingredients in Soliqua, have shown potential risks to the developing fetus. However, it is important to note that poorly controlled diabetes during pregnancy can lead to serious complications for both the mother and the baby, including birth defects, high blood pressure, and pregnancy loss.

Because the risks are not fully understood, healthcare providers often recommend using insulin alone to manage blood sugar levels during pregnancy. If you are pregnant or planning to become pregnant, you should discuss the benefits and risks of your treatment options with your doctor.

Breastfeeding

It is currently unknown if Soliqua passes into human breast milk or how it might affect a nursing infant. Many medications can be excreted in breast milk and may cause side effects in a baby. Because of the potential for adverse reactions, a decision must be made whether to stop breastfeeding or stop using the medication.

If you are breastfeeding or planning to breastfeed, consult your healthcare professional to determine the safest course of action for you and your child.

Available Forms

Soliqua is provided as a clear, colorless solution for injection. It is available in the following form:

• Pre-filled disposable pen: A single-patient-use pen used to deliver the medication subcutaneously.

This medication is a combination product containing a long-acting human insulin analog and a glucagon-like peptide-1 receptor agonist. It is designed to be used with disposable needles.

FDA Approval and Indications

Soliqua 100/33 is approved by the U.S. Food and Drug Administration (FDA) for use in adults with type 2 diabetes. It is a combination of two medications: insulin glargine, a long-acting insulin, and lixisenatide, a GLP-1 receptor agonist. It is intended to be used alongside diet and exercise to manage blood glucose levels.

Safety Communications and Monitoring

The FDA has monitored several safety signals related to Soliqua through its adverse event reporting systems:

• Medication Errors: The FDA identified potential risks regarding medication errors, such as receiving the wrong dose or the wrong drug, in early 2018.
• Anaphylactic Reactions: In 2020, the FDA evaluated reports of serious allergic reactions, including anaphylaxis, associated with the medication.
• Suicidal Ideation: The FDA has conducted evaluations regarding reports of suicidal thoughts or actions in patients taking GLP-1 receptor agonists. As of early 2024, the FDA's preliminary review has not found evidence that these medications cause such thoughts or actions, but the agency continues to study the issue.

There are no boxed warnings currently listed for Soliqua in the provided regulatory documentation.

Factors Influencing Cost

The amount you pay for Soliqua is determined by several variables:

• Insurance Plan: Your specific health insurance provider and plan formulary will dictate your copay or coinsurance. Some plans may require prior authorization from a healthcare provider before they agree to cover the medication.
• Pharmacy Selection: Prices may differ between local retail pharmacies, large chains, and mail-order pharmacy services.
• Medicare and Medicaid: Coverage for Soliqua under government programs like Medicare Part D or Medicaid varies by state and individual plan details.

Generic Availability

Soliqua is a brand-name medication containing insulin glargine and lixisenatide. Currently, there is no generic version available. Brand-name drugs typically cost more than generic alternatives because they are protected by patents that prevent other companies from making the same medication for a set period.

Financial Assistance Programs

There are several options that may help reduce the out-of-pocket cost of Soliqua:

• Manufacturer Savings Cards: The drug manufacturer may offer copay cards for patients with commercial insurance. These cards can lower the monthly cost for eligible individuals.
• Patient Assistance Programs: Programs such as Sanofi Patient Connection may provide the medication at a reduced cost or for free to patients who meet specific income requirements or who do not have insurance coverage.
• Extra Help: Low-income individuals with Medicare may qualify for the Extra Help program, which assists with the costs of prescription drug premiums and copays.